Jin Medical International Ltd (ZJYL) Stock Analysis
Verdict: AVOID
Severe revenue contraction and negative FCF outweigh deep-value multiples; the model views recent gains as a dead-cat bounce.
Investment score: 38/100
Analysis as of
Is Jin Medical International Ltd stock worth reviewing? The TradeMates thesis
The model identifies ZJYL as a high-risk microcap with deteriorating fundamentals masked by a low P/B ratio.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Jin Medical International Ltd opportunities and risks
What speaks for ZJYL
- Asset-Heavy Valuation Support
What speaks against ZJYL
- Negative Free Cash Flow and Liquidity Crunch
Peers and competitors
- 2216.HK
- 2297.HK
- BDMD
- TANAF
- GENX
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ZJYL | 14.7x | 0.9x | 39.5x | 30.6% | 5.9% | -41.4% |
| BDMD | n/a | 2.3x | n/a | 83.8% | -121.0% | -2.7% |
| GENX | 0.0x | 0.0x | n/a | 88.8% | 10.6% | 29552.9% |
| Peer median | n/a | 1.1x | n/a | 86.3% | -55.2% | 14775.1% |
Frequently asked questions about Jin Medical International Ltd (ZJYL)
Is ZJYL stock a good investment?
The TradeMates model rates Jin Medical International Ltd as AVOID with an investment score of 38/100. The model identifies ZJYL as a high-risk microcap with deteriorating fundamentals masked by a low P/B ratio. This is algorithmic model output, not personal investment advice.
Is ZJYL stock a buy?
The TradeMates model verdict for ZJYL is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.